SCHEMBL2656865

SCHEMBL2656865

COC(=O)CSc1cnc(N)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 5/20 0.49
CCNE2 O96020 4/20 0.49
CCNE1 P24864 4/20 0.49
CCNB2 O95067 3/20 0.49
CDK1 P06493 3/20 0.49
CDK4 P11802 3/20 0.49
CCNB1 P14635 3/20 0.49
CCND1 P24385 3/20 0.49
CCNB3 Q8WWL7 3/20 0.49
ALDH1A1 P00352 5/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
NOTUM Q6P988 1/20 0.43
HPGD P15428 3/20 0.42
APOBEC3G Q9HC16 1/20 0.42
MAPK1 P28482 3/20 0.42
HSD17B10 Q99714 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16724105 0.85 SMN1; SMN2 (0.41) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL688576 0.85 CCNB2 (0.64) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL19018619 0.81 HSP90AB1 (0.44) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL2606389 0.80 MYC (0.44) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL2481820 0.78 CCNB2 (0.56) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL999731 0.74 SMN1; SMN2 (0.56) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL16086926 0.73 CDK2 (0.49) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL1636834 0.72 SMN1; SMN2 (0.71) ALDH1A1MAPTSMN1; SMN2HSD17B10HTT
SCHEMBL16086614 0.72 CDK2 (0.46) CDK2CCNE2CCNE1ALDH1A1MAPT
SCHEMBL5875895 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921576-B2 Spiroindoline compound, and medicinal agent comprising same KOWA COMPANY, LTD. (JP) 2014-12-30 US disclosed
US-20140309207-A1 NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME KOWA COMPANY, LTD (JP) 2014-10-16 US disclosed
EP-2781521-A1 NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2014-09-24 EP disclosed
US-8362049-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2013-01-29 US disclosed
US-8318778-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2012-11-27 US disclosed
US-20120165375-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2012-06-28 US disclosed
US-20100041711-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2010-02-18 US disclosed
EP-2099777-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2009-09-16 EP disclosed
WO-2008084044-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309207-A1 NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME GCKR, GCK, GALK1 CDK2 552/4885CCNE2 1668/4885CCNE1 1437/4885
US-20100041711-A1 Urea Glucokinase Activators GCK, GCKR, HK2 CDK2 381/4885CCNE2 2292/4885CCNE1 3375/4885
US-20120165375-A1 Urea Glucokinase Activators GCK, GCKR, HK2 CDK2 381/4885CCNE2 2292/4885CCNE1 3375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.